In addition to viral and environmental/behavioural factors, host genetic diversity is believed
to contribute to the spectrum of clinical outcomes in hepatitis C virus (HCV) infection. This …

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC)
worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in …

Background & Aims While the gold standard in the assessment of liver fibrosis remains liver
biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB) …

Interferon stimulates the expression of a number of genes encoding enzymes with antiviral
activities, including myxovirus resistance-1 (MxA), 2-5-oligoadenylate synthetase 1 (OAS-1) …

BACKGROUND Efficacy trials have shown that antiviral therapy improves the outcomes of
patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding …

Background The nucleos (t) ide analogues (NAs) entecavir (ETV), tenofovir disoproxil
fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients …

Host genetic factors have been reported to influence the natural history of hepatitis C virus
(HCV) infection. We examined whether variation in interleukin 10 (IL-10) and tumor necrosis …

We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had
baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA≥ 9 log10 …

Pro-inflammatory cytokines including tumour necrosis factor (TNF) mediate the
pathogenesis of hepatitis C virus (HCV) infection. The distribution of TNF gene …

Background & Aims The comparative risk of hepatocellular carcinoma (HCC) in patients with
chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) …